Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Por um escritor misterioso
Descrição
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. - Abstract - Europe PMC
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
RCSB PDB - 8BYU: Crystal Structure of HexaBody-CD38 Fab in complex with CD38
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti -CD38 antibody drug for treating multiple myeloma - ScienceDirect
Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. - Abstract - Europe PMC
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. - Abstract - Europe PMC
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
de
por adulto (o preço varia de acordo com o tamanho do grupo)
